Lilly’s oral weight-loss pill Foundayo cuts OSA severity by up to ~44% in Phase 3; label expansion filing planned by year-end (Earnings)

Financedesk view

Lilly’s oral weight-loss pill Foundayo cuts OSA severity by up to ~44% in Phase 3; label expansion filing planned by year-end (Earnings)

Eli Lilly reported Phase 3 ATTAIN-OSA results showing Foundayo (orforglipron) significantly reduced the apnea-hypopnea index at 52 weeks in adults with moderate…

READ THE DAY'S DIGEST →

Sciencedesk view

Lilly’s oral GLP-1 pill Foundayo (orforglipron) cuts obstructive sleep apnea severity in Phase 3 (metabolism & sleep)

Eli Lilly on November 9 reported ATTAIN-OSA Phase 3 results (also in JAMA): in adults with moderate-to-severe OSA and obesity or overweight, once-daily oral orf…

READ THE DAY'S DIGEST →